View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 24, 2022

mRNA vaccines: who is the frontrunner in clinical trial initiations beyond Covid-19?

Although messenger RNA (mRNA) vaccines have been studied for decades, they have been greatly exposed due to the Covid-19 pandemic.

By GlobalData Healthcare

Regulatory bodies and sponsors alike are looking to expand the knowledge they have gained from the Covid-19 pandemic to other indications. Although messenger RNA (mRNA) vaccines have been studied for decades, they have been greatly exposed due to the pandemic. Companies are now looking beyond Covid-19 to treat other indications with the same mRNA technology, since it expedites vaccine development as mRNA vaccines are designed primarily using computers.

When looking at the top sponsors, Moderna currently has the most planned and ongoing mRNA vaccine trials outside of Covid-19, with the top indication being cytomegalovirus infections. Moderna had expected a Phase I trial completion on 15 February 2022 for its clinical trial with mRNA-1647 for the treatment of cytomegalovirus infections, but no update has yet been released. Moderna is also expecting a Phase I/II trial completion in June this year with its mRNA-1010 for the treatment of influenza.

One trial to note from Moderna is IAVI G002, a Phase I investigation for the treatment of human immunodeficiency virus (HIV). This trial, which recently announced initiation last month, will enrol patients at four sites across the US. A total of 56 HIV-negative patients will be enrolled, with 48 receiving one or two doses of the mRNA vaccine (mRNA-1644); 32 will receive mRNA-1644v2-Core and eight will receive only the boost immunogen.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy